Recent studies show increased expression of human epidermal growth factor receptor 2 (HER2) in cervical cancer, but the efficacy of anti‐HER2 therapy remains under‐researched. Here, we present a case of recurrent HER2‐positive serous carcinoma, presumably arising in the cervix, diagnosed by comprehensive genomic profiling, which responded to trastuzumab. The patient underwent a radical hysterectomy with concurrent adjuvant chemoradiotherapy. One year after surgery, the patient experienced recurrence (multiple lymph node metastases). She underwent chemotherapy and subsequent comprehensive genomic profiling, which revealed HER2 positivity. Despite treatment, the lymph node and peritoneal metastases progressed. Therefore, combination chemotherapy with paclitaxel and trastuzumab was initiated. Subsequently, the patient's clinical symptoms improved considerably, and good health was maintained for 8 months. This report highlights the importance of comprehensive genomic profiling and targeted therapies when standard treatments fail.

中文翻译：

---

紫杉醇和曲妥珠单抗联合治疗人表皮生长因子受体 2 阳性复发性子宫颈浆液性癌：病例报告


最近的研究表明，人表皮生长因子受体 2 （HER2） 在宫颈癌中的表达增加，但抗 HER2 疗法的疗效仍未得到充分研究。在这里，我们介绍了一例复发性 HER2 阳性浆液性癌，可能起源于宫颈，通过综合基因组分析诊断，对曲妥珠单抗有反应。患者接受了根治性子宫切除术，同时进行辅助放化疗。术后 1 年，患者出现复发 （多发性淋巴结转移）。她接受了化疗和随后的综合基因组分析，结果显示 HER2 阳性。尽管接受了治疗，淋巴结和腹膜转移仍进展。因此，开始了紫杉醇和曲妥珠单抗的联合化疗。随后，患者临床症状明显改善，身体状况维持 8 个月。本报告强调了当标准治疗失败时，全面基因组分析和靶向治疗的重要性。